iRGD-mediated core-shell nanoparticles loading carmustine and O⁶-benzylguanine for glioma therapy

References

• White KL, Passipieri M, Bunch TD, et al. Effects of arginine-glycine-aspartic acid (RGD) containing snake venom peptides on parthenogenetic development and in vitro fertilization of bovine oocytes. Mol Reprod Dev 2007;74:88–96.
   PubMed Web of Science ®Google Scholar
• Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005;8:381–402.
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012;9:2961–73.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510–20.
   PubMed Web of Science ®Google Scholar
• Hamilton AM, Aidoudi-Ahmed S, Sharma S, et al. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J Mol Med (Berl) 2015;93:991–1001.
   PubMed Web of Science ®Google Scholar
• Cun X, Chen J, Ruan S, et al. A novel strategy through combining iRGD peptide with tumor-microenvironment-responsive and multistage nanoparticles for deep tumor penetration. ACS Appl Mater Interfaces 2015;7:27458–66.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang X, Liu Y, et al. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 2014;35:8735–47.
   PubMed Web of Science ®Google Scholar
• Paoletti P. Therapeutic strategy for central nervous system tumors: present status, criticism and potential. J Neurosurg Sci 1984;28:51–60.
   PubMedGoogle Scholar
• Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol 2015;122:367–82.
   PubMed Web of Science ®Google Scholar
• Seong H, An TK, Khang G, et al. BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm 2003;251:1–12.
   PubMed Web of Science ®Google Scholar
• Moynihan TJ, Grossman SA. The role of chemotherapy in the treatment of primary tumors of the central nervous system. Cancer Invest 1994;12:88–97.
   PubMed Web of Science ®Google Scholar
• Figueiredo EG, Faria JW, Teixeira MJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. Arq Neuropsiquiatr 2010;68:778–82.
   PubMed Web of Science ®Google Scholar
• Hua MY, Liu HL, Yang HW, et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials 2011;32:516–27.
   PubMed Web of Science ®Google Scholar
• Wiencke JK, Wiemels J. Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res 1995;339:91–119.
   PubMed Web of Science ®Google Scholar
• Ryan CW, Dolan ME, Brockstein BB, et al. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 2006;58:634–9.
   PubMed Web of Science ®Google Scholar
• Grossman R, Burger P, Soudry E, et al. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. J Clin Neurosci 2015;22:1938–42.
   PubMed Web of Science ®Google Scholar
• Stefan TL, Ingalls ST, Minkler PE, et al. Simultaneous determination of O6-benzylguanine and 8-oxo-O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;704:289–98.
   PubMed Web of Science ®Google Scholar
• Blumenthal DT, Rankin C, Stelzer KJ, et al. A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 2015;20:650–8.
   PubMed Web of Science ®Google Scholar
• Kaina B, Margison GP, Christmann M. Targeting O(6)-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 2010;67:3663–81.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao S. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 2007;329:122–8.
   PubMed Web of Science ®Google Scholar
• Qian L, Zheng J, Wang K, et al. Cationic core-shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy . Biomaterials 2013;34:8968–78.
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian L, Hong M, et al. RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv Mater 2011;23:H84–9.
   PubMed Web of Science ®Google Scholar
• Saadati R, Dadashzadeh S. Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation. Int J Pharm 2014;464:135–44.
   PubMed Web of Science ®Google Scholar
• Ulrich TA, Jain A, Tanner K, et al. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. Biomaterials 2010;31:1875–84.
   PubMed Web of Science ®Google Scholar
• Akbar U, Jones T, Winestone J, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. J Neurooncol 2009;94:203–12.
   PubMed Web of Science ®Google Scholar
• Black KC, Wang Y, Luehmann HP, et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyzes of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano 2014;8:4385–94.
   PubMed Web of Science ®Google Scholar
• Shahbazi MA, Herranz B, Santos HA. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter 2012;2:296–312.
   PubMedGoogle Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752–6.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. The RGD story: a personal account. Matrix Biol 2003;22:459–65.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83–90.
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA2009;106:16157–62.
   PubMed Web of Science ®Google Scholar
• DelNero P, Lane M, Verbridge SS, et al. 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. Biomaterials 2015;55:110–18.
   PubMed Web of Science ®Google Scholar
• Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005;15:365–77.
   PubMed Web of Science ®Google Scholar
• Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601–10.
   PubMed Web of Science ®Google Scholar
• Kim SA, Lee EK, Kuh HJ. Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition in vitro. Exp Cell Res 2015;335:187–96.
   PubMed Web of Science ®Google Scholar
• Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 2009;113:143–8.
   PubMed Web of Science ®Google Scholar
• Pedersen JA, Swartz MA. Mechanobiology in the third dimension. Ann Biomed Eng 2005;33:1469–90.
   PubMed Web of Science ®Google Scholar
• Ulrich TA, Lee TG, Shon HK, et al. Microscale mechanisms of agarose-induced disruption of collagen remodeling. Biomaterials 2011;32:5633–42.
   PubMed Web of Science ®Google Scholar
• Yang YL, Motte S, Kaufman LJ. Pore size variable type I collagen gels and their interaction with glioma cells. Biomaterials 2010;31:5678–88.
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000;6:3025–31.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031–5.
   PubMed Web of Science ®Google Scholar
• Gu G, Gao X, Hu Q, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 2013;34:5138–48.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39–43.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Clair P, Temsamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target 2002;10:309–15.
   PubMed Web of Science ®Google Scholar
• Che C, Yang G, Thiot C, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 2010;53:2814–24.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 2012;24:3747–56.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137–72.
   PubMed Web of Science ®Google Scholar
• Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003;55:403–19.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004;277:39–61.
   PubMed Web of Science ®Google Scholar
• Yang R, Shim WS, Cui FD, et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 2009;371:142–7.
   PubMed Web of Science ®Google Scholar